For patients with R/R DLBCL
who are not eligible for or refuse ASCT 1
MINJUVI® + Lenalidomide
right after the first relapse
  • In 2L: More than 50 % CR- rate2,a
  • More than 50 % survival probability after 5 years in 2L2
  • Chemotherapy-free „off-the-shelf“ immunotherapy with a favorable safety profile2
Indication:1

MINJUVI® is indicated in combination with lenalidomide followed by MINJUVI® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least one line of systemic CD20-targeted antibody therapy who are not eligible for autologous stem cell transplantation (ASCT).1